A Simple Saliva Test Is All It Takes for Congenital CMV Detection

Tuesday, August 6, 11:30 – 11:50 a.m.
Exhibit Hall, Theater 3
Supported by Meridian Bioscience Inc.

Overview

This program will review the impact of congenital CMV as the number one cause of non-genetic deafness in newborns, including the current testing algorithms, the different sample types, and their advantages and disadvantages. The majority of CMV positive babies are born asymptomatic, so unless tested directly for the virus congenital CMV infection can be missed. Relying on newborn hearing screening alone is not sufficient to detect all affected babies, given that 43% of CMV positive babies will pass their hearing test. Now there is an easy alternative to testing all babies for potential congenital CMV infection. Alethia CMV from Meridian Bioscience is the first FDA-cleared saliva based molecular test for the detection of congenital CMV in newborns < 21 days. This simple molecular test provides accurate results in < 1 hour from an easy-to-collect saliva swab sample.

Outcomes

After attending the session, participants will be able to:

  • Have a deeper understanding of the impact of congenital CMV on newborns, the current practices and the legislations driving congenital CMV testing.
  • Bring back knowledge and educate their institution on the need and importance of congenital CMV testing.
  • Know and understand the new alternative for congenital CMV routine testing.

Speaker

Dr. Ted Schutzbank
Scientific Affairs Manager
Meridian Bioscience
Cincinnati, OH